Inhibikase Therapeutics, Inc. (IKT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Inhibikase Therapeutics, Inc. (IKT) closed at USD 1.80 on 2026-10-14, a change of +22.4 % over the past year, with a market capitalization of USD 255.35M.

Inhibikase Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Inhibikase Therapeutics, Inc. key figures

Previous close

USD 1.80 (2026-10-14)

1-year change

+22.4 %

Market cap

USD 255.35M

Enterprise value

USD 174.18M

P/E ratio (trailing)

-4.26

P/E ratio (forward)

-4.36

EPS (trailing)

-0.43

EPS (forward)

-0.42

PEG ratio

n/a

Price to book

2.08

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

34.84

Employees

35

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Inhibikase Therapeutics, Inc. and compare it with other stocks.